Pooled analysis of Halaven in Breast Cancer published - Eisai

The results from a pooled analysis of two Phase III trials of Halaven (eribulin), from Eisai, in Breast Cancer patients have been published in Breast Cancer Research and Treatment. Findings from the pooled analysis show that eribulin improves overall survival in women compared to control. This overall survival benefit was observed in women with human epidermal growth-factor receptor-2 (HER2) negative Breast Cancer and triple negative Breast Cancer (TNBC). The pooled analysis examined data from two pivotal Phase III studies in 1,864 women; EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Treatment of Physician's Choice Versus Eribulin) and Study 301. eribulin was found to improve significantly overall survival vs. control in the ITT population (15.2 vs 12.8 months).

A significant overall survival benefit was observed in women with HER2 negative breast cancer (15.2 vs 12.3 months), a subtype that affects an estimated 85% of women with breast cancer. This overall survival benefit was also seen in people with TNBC, (12.9 vs 8.2 months), but not in women with HER2 positive breast cancer (13.5 vs 12.2 months). There were no noticeable differences in the tolerability and safety data previously shown in the EMBRACE study (Study 305) and Study 301.